A Phase 1 interventional study of GS-2426 in advanced MTAP-deleted solid tumors

Study Description

A first-in-human study testing a new cancer drug called GS-2426 in patients with advanced solid tumors that have a specific genetic change (MTAP deletion)

Study Details

Registry ID:

NCT07601243

Conditions:

Advanced Solid Tumors

Phase:

Phase 1

Target Enrollment:

174 participants

Start Date:

June 2, 2026

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (4 sites)

• Memorial Sloan Kettering Cancer Center
  New York, New YorkUnited States, United States
• START Astera, LLC
  East Brunswick, New JerseyUnited States, United States
• START Midwest
  Grand Rapids, MichiganUnited States, United States
• START San Antonio, LLC
  San Antonio, TexasUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →